Non-alcoholic fatty liver disease in obese adults: Clinical aspects and current management strategies

Clinical Obesity

Volumn 4, Issue 5, 2014, Pages 243-253

  Pallayova, M ^a   Taheri, S ^b,c  

^a Med Faculty of Safarik University   (Slovakia)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c NONE   (Qatar)

Author keywords

Clinical management; Non alcoholic fatty liver disease; Obesity

Indexed keywords

EXENDIN 4; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIRAGLUTIDE; TETRAHYDROLIPSTATIN;

BARIATRIC SURGERY; COMORBIDITY; DISEASE ASSOCIATION; FATTY LIVER; HUMAN; INFLAMMATION; LIFESTYLE MODIFICATION; MOLECULAR PATHOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; PREVALENCE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SYNDROME DELINEATION; TREATMENT RESPONSE; WEIGHT REDUCTION;

EID: 85047103352     PISSN: 17588103     EISSN: 17588111     Source Type: Journal    
DOI: 10.1111/cob.12068     Document Type: Review

References (148)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-1231.
2. Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol 2012; 56: 1384-1391.
3. Duan XY, Qiao L, Fan JG. Clinical features of nonalcoholic fatty liver disease-associated hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2012; 11: 18-27.
4. Rosmorduc O, Fartoux L. HCC and NASH: how strong is the clinical demonstration? Clin Res Hepatol Gastroenterol 2012; 36: 202-208.
5. Kim CH, Younossi ZM. Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. Cleve Clin J Med 2008; 75: 721-728.
6. Chalasani N, Younossi Z, Lavine JE et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005-2023.
7. Lazo M, Clark JM. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis 2008; 28: 339-350.
8. Abdelmalek MF, Diehl AM. Nonalcoholic fatty liver disease as a complication of insulin resistance. Med Clin North Am 2007; 91: 1125-1149. ix.
9. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-2474.
10. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and nonalcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34: 274-285.
11. Abenavoli L, Beaugrand M. Transient elastography in non-alcoholic fatty liver disease. Ann Hepatol 2012; 11: 172-178.
12. Kallwitz ER, Kumar M, Aggarwal R et al. Ethnicity and nonalcoholic fatty liver disease in an obesity clinic: the impact of triglycerides. Dig Dis Sci 2008; 53: 1358-1363.
13. Williams CD, Stengel J, Asike MI et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011; 140: 124-131.
14. Toshimitsu K, Matsuura B, Ohkubo I et al. Dietary habits and nutrient intake in non-alcoholic steatohepatitis. Nutrition 2007; 23: 46-52.
15. Sookoian S, Pirola CJ. Obstructive sleep apnea is associated with fatty liver and abnormal liver enzymes: a meta-analysis. Obes Surg 2013; 23: 1815-1825.
16. Dawson AJ, Sathypalan T, Smithson JA et al. A comparison of cardiovascular risk indices in patients with polycystic ovary syndrome with and without co-existing non-alcoholic fatty liver disease. Clin Endocrinol (Oxf) 2014; 80: 843-849.
17. Tanaka N, Horiuchi A, Yokoyama T et al. Clinical characteristics of de novo nonalcoholic fatty liver disease following pancreaticoduodenectomy. J Gastroenterol 2011; 46: 758-768.
18. Hazlehurst JM, Tomlinson JW. Mechanisms in endocrinology: non-alcoholic fatty liver disease in common endocrine disorders. Eur J Endocrinol 2013; 169: R27-R37.
19. Malhi H, Gores GJ. Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis 2008; 28: 360-369.
20. York LW, Puthalapattu S, Wu GY. Nonalcoholic fatty liver disease and low-carbohydrate diets. Annu Rev Nutr 2009; 29: 365-379.
21. Pagano G, Pacini G, Musso G et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 2002; 35: 367-372.
22. Postic C, Girard J. The role of the lipogenic pathway in the development of hepatic steatosis. Diabetes Metab 2008; 34(6 Pt 2): 643-648.
23. Yang SQ, Lin HZ, Lane MD, Clemens M, Diehl AM. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci USA 1997; 94: 2557-2562.
24. George DK, Goldwurm S, Macdonald GA et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998; 114: 311-318.
25. Sanyal AJ, Campbell-Sargent C, Mirshahi F et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120: 1183-1192.
26. Abu-Shanab A, Quigley EM. The role of the gut microbiota in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2010; 7: 691-701.
27. Alisi A, Ceccarelli S, Panera N, Nobili V. Causative role of gut microbiota in non-alcoholic fatty liver disease pathogenesis. Front Cell Infect Microbiol 2012; 2: 132.
28. Compare D, Coccoli P, Rocco A et al. Gut-liver axis: the impact of gut microbiota on nonalcoholic fatty liver disease. Nut Metab Cardiovasc Dis 2012; 22: 471-476.
29. Boursier J, Rawls JF, Diehl AM. Obese humans with nonalcoholic fatty liver disease display alterations in fecal microbiota and volatile organic compounds. Clin Gastroenterol Hepatol 2013; 11: 876-878.
30. Frasinariu OE, Ceccarelli S, Alisi A, Moraru E, Nobili V. Gut-liver axis and fibrosis in nonalcoholic fatty liver disease: an input for novel therapies. Dig Liver Dis 2013; 45: 543-551.
31. Quigley EM, Stanton C, Murphy EF. The gut microbiota and the liver. Pathophysiological and clinical implications. J Hepatol 2013; 58: 1020-1027.
32. Raman M, Ahmed I, Gillevet PM et al. Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2013; 11: 868-875. e1-3.
33. Visschers RG, Luyer MD, Schaap FG, Olde Damink SW, Soeters PB. The gut-liver axis. Curr Opin Clin Nutr Metab Care 2013; 16: 576-581.
34. Wong VW, Tse CH, Lam TT et al. Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis-a longitudinal study. PLoS ONE 2013; 8: e62885.
35. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature 2006; 444: 1022e3.
36. Zhu L, Baker SS, Gill C et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology 2013; 57: 601-609.
37. Bugianesi E, Leone N, Vanni E et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123: 134-140.
38. Marrero JA, Fontana RJ, Su GL et al. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002; 36: 1349-1354.
39. Salomao M, Remotti H, Vaughan R et al. The steatohepatitic variant of hepatocellular carcinoma and its association with underlying steatohepatitis. Hum Pathol 2012; 43: 737-746.
40. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010; 363: 1341-1350.
41. Bhatia LS, Curzen NP, Calder PC, Byrne CD. Nonalcoholic fatty liver disease: a new and important cardiovascular risk factor? Eur Heart J 2012; 33: 1190-1200.
42. Goland S, Shimoni S, Zornitzki T et al. Cardiac abnormalities as a new manifestation of nonalcoholic fatty liver disease: echocardiographic and tissue Doppler imaging assessment. J Clin Gastroenterol 2006; 40: 949-955.
43. Perseghin G, Lattuada G, De Cobelli F et al. Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver. Hepatology 2008; 47: 51-58.
44. Bonapace S, Perseghin G, Molon G et al. Nonalcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in patients with type 2 diabetes. Diabetes Care 2012; 35: 389-395.
45. Hallsworth K, Hollingsworth KG, Thoma C et al. Cardiac structure and function are altered in adults with non-alcoholic fatty liver disease. J Hepatol 2013; 58: 757-762.
46. Targher G, Valbusa F, Bonapace S et al. Non-alcoholic fatty liver disease is associated with an increased incidence of atrial fibrillation in patients with type 2 diabetes. PLoS ONE 2013; 8: e57183.
47. Gaudio E, Nobili V, Franchitto A, Onori P, Carpino G. Nonalcoholic fatty liver disease and atherosclerosis. Intern Emerg Med 2012; 7(Suppl. 3): S297-S305.
48. Makadia SS, Blaha M, Keenan T et al. Relation of hepatic steatosis to atherogenic dyslipidemia. Am J Cardiol 2013; 112: 1599-1604.
49. Verrijken A, Francque S, Mertens I et al. Prothrombotic factors in histologically proven nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology 2014; 59: 121-129.
50. Targher G, Bertolini L, Rodella S et al. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients. Diabetologia 2008; 51: 444-450.
51. Yun KE, Shin CY, Yoon YS, Park HS. Elevated alanine aminotransferase levels predict mortality from cardiovascular disease and diabetes in Koreans. Atherosclerosis 2009; 205: 533-537.
52. Hwang ST, Cho YK, Yun JW et al. Impact of NAFLD on microalbuminuria in patients with prediabetes and diabetes. Intern Med J 2010; 40: 437-442.
53. Targher G, Bertolini L, Chonchol M et al. Nonalcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and retinopathy in type 1 diabetic patients. Diabetologia 2010; 53: 1341-1348.
54. Targher G, Chonchol M, Bertolini L et al. Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis. Clin J Am Soc Nephrol 2010; 5: 2166-2171.
55. Targher G, Kendrick J, Smits G, Chonchol M. Relationship between serum gamma-glutamyltransferase concentrations and chronic kidney disease in the United States population. Findings from the National Health and Nutrition Examination Survey 2001-2006. Nutr Metab Cardiovasc Dis 2010; 20: 583-590.
56. Yasui K, Sumida Y, Mori Y et al. Nonalcoholic steatohepatitis and increased risk of chronic kidney disease. Metabolism 2011; 60: 735-739.
57. Yilmaz Y, Alahdab YO, Yonal O et al. Microalbuminuria in nondiabetic patients with nonalcoholic fatty liver disease: association with liver fibrosis. Metabolism 2010; 59: 1327-1330.
58. Targher G, Pichiri I, Zoppini G, Trombetta M, Bonora E. Increased prevalence of chronic kidney disease in patients with Type 1 diabetes and non-alcoholic fatty liver. Diabet Med 2012; 29: 220-226.
59. Lee DH, Jacobs DR, Gross M, Steffes M. Serum gammaglutamyltransferase was differently associated with microalbuminuria by status of hypertension and diabetes: the Coronary Artery Risk Development in Young Adults (CARDIA) study. Clin Chem 2005; 51: 1185-1191.
60. Ryu S, Chang Y, Kim DI, Kim WS, Suh BS. Gammaglutamyltransferase as a predictor of chronic kidney disease in nonhypertensive and nondiabetic Korean men. Clin Chem 2007; 53: 71-77.
61. Chang Y, Ryu S, Sung E et al. Nonalcoholic fatty liver disease predicts chronic kidney disease in nonhypertensive and nondiabetic Korean men. Metabolism 2008; 57: 569-576.
62. Targher G, Chonchol M, Bertolini L et al. Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease. J Am Soc Nephrol 2008; 19: 1564-1570.
63. Machado MV, Gonçalves S, Carepa F et al. Impaired renal function in morbid obese patients with nonalcoholic fatty liver disease. Liver Int 2012; 32: 241-248.
64. Ix JH, Sharma K. Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: the roles of fetuin-A, adiponectin, and AMPK. J Am Soc Nephrol 2010; 21: 406-412.
65. Targher G, Chonchol M, Zoppini G, Abaterusso C, Bonora E. Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease: is there a link? J Hepatol 2011; 54: 1020-1029.
66. Sirota JC, McFann K, Targher G, Chonchol M, Jalal DI. Association between nonalcoholic liver disease and chronic kidney disease: an ultrasound analysis from NHANES 1988-1994. Am J Nephrol 2012; 36: 466-471.
67. Choi JH, Rhee EJ, Bae JC et al. Increased risk of type 2 diabetes in subjects with both elevated liver enzymes and ultrasonographically diagnosed nonalcoholic fatty liver disease: a 4-year longitudinal study. Arch Med Res 2013; 44: 115-120.
68. Chung GE, Kim D, Kim W et al. Non-alcoholic fatty liver disease across the spectrum of hypothyroidism. J Hepatol 2012; 57: 150-156.
69. Youssef NA, Abdelmalek MF, Binks M et al. Associations of depression, anxiety and antidepressants with histological severity of nonalcoholic fatty liver disease. Liver Int 2013; 33: 1062-1070.
70. Reid AE. Nonalcoholic steatohepatitis. Gastroenterology 2001; 121: 710-723.
71. Wilkins T, Tadkod A, Hepburn I, Schade RR. Nonalcoholic fatty liver disease: diagnosis and management. Am Fam Physician 2013; 88: 35-42.
72. Ma X, Holalkere NS, Kambadakone RA et al. Imaging-based quantification of hepatic fat: methods and clinical applications. Radiographics 2009; 29: 1253-1277.
73. Festi D, Schiumerini R, Marzi L et al. Review article: the diagnosis of non-alcoholic fatty liver disease - availability and accuracy of non-invasive methods. Aliment Pharmacol Ther 2013; 37: 392-400.
74. Mennesson N, Dumortier J, Hervieu V et al. Liver steatosis quantification using magnetic resonance imaging: a prospective comparative study with liver biopsy. J Comput Assist Tomogr 2009; 33: 672-677.
75. Choudhury J, Sanyal AJ. Clinical aspects of fatty liver disease. Semin Liver Dis 2004; 24: 349-362.
76. Seetho IW, Wilding JPH. How to approach endocrine assessment in severe obesity? Clin Endocrinol 2013; 79: 163-167.
77. Jaffer OS, Lung PFC, Bosanac D, Shah A, Sidhu PS. Is ultrasound elastography of the liver ready to replace biopsy? A critical review of the current techniques. Ultrasound 2012; 20: 24-32.
78. Boursier J, Rousselet M-C, Aube C, Cales P. Liver fibrosis in patients with non-alcoholic fatty liver disease: diagnostic options in clinical practice. Expert Opin Med Diagn 2012; 6: 381-394.
79. Kim D, Kim WR, Talwalkar JA, Kim HJ, Ehman RL. Advanced fibrosis in nonalcoholic fatty liver disease: noninvasive assessment with MR elastography. Radiology 2013; 268: 411-419.
80. Friedrich-Rust M, Romen D, Vermehren J et al. Acoustic radiation force impulse-imaging and transient elastography for non-invasive assessment of liver fibrosis and steatosis in NAFLD. Eur J Radiol 2012; 81: e325-e331.
81. Schmeltzer PA, Talwalkar JA. Noninvasive tools to assess hepatic fibrosis: ready for prime time? Gastroenterol Clin North Am 2011; 40: 507-521.
82. Angulo P, Hui JM, Marchesini G et al. The NAFLD fibrosis score A noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45: 846-854.
83. Angulo P, Bugianesi E, Bjornsson ES et al. Simple non-invasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2013; 145: 782-789. e4.
84. Fierbinteanu-Braticevici C, Plesca DA, Tribus L, Panaitescu E, Braticevici B. The role of 13C-methacetin breath test for the noninvasive evaluation of nonalcoholic fatty liver disease. J Gastrointestin Liver Dis 2013; 22: 149-156.
85. Orešič M, Hyötyläinen T, Kotronen A et al. Prediction of non-alcoholic fatty-liver disease and liver fat content by serum molecular lipids. Diabetologia 2013; 56: 2266-2274.
86. Zenirler S, Degertekin CK, Erkan G et al. Serum liver fatty acid binding protein shows good correlation with liver histology in NASH. Hepatogastroenterology 2013; 60: 1095-1100.
87. National Institute for Health and Clinical Excellence. Clinical Guideline 43, Obesity: Guidance on the Prevention, Identification, Assessment and Management of Overweight and Obesity in Adults and Children. National Institute for Clinical Excellence: London, 2006. [WWW document]. URL: http://www.nice.org.uk/guidance/CG43 (accessed 2014).
88. Eckard C, Cole R, Lockwood J et al. Prospective histopathologic evaluation of lifestyle modification in nonalcoholic fatty liver disease: a randomized trial. Therap Adv Gastroenterol 2013; 6: 249-259.
89. Shojaee-Moradie F, Baynes KC, Pentecost C et al. Exercise training reduces fatty acid availability and improves the insulin sensitivity of glucose metabolism. Diabetologia 2007; 50: 404-413.
90. Johnson NA, Sachinwalla T, Walton DW et al. Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology 2009; 50: 1105-1112.
91. Hallsworth K, Fattakhova G, Hollingsworth KG et al. Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. Gut 2011; 60: 1278-1283.
92. Sullivan S, Kirk EP, Mittendorfer B, Patterson BW, Klein S. Randomized trial of exercise effect on intrahepatic triglyceride content and lipid kinetics in nonalcoholic fatty liver disease. Hepatology 2012; 55: 1738-1745.
93. Solga S, Alkhuraishe AR, Clark JM et al. Dietary composition and nonalcoholic fatty liver disease. Dig Dis Sci 2004; 49: 1578-1583.
94. Tendler D, Lin S, Yancy WS Jr et al. The effect of a lowcarbohydrate, ketogenic diet on nonalcoholic fatty liver disease: a pilot study. Dig Dis Sci 2007; 52: 589-593.
95. Kirk E, Reeds D, Finck B et al. Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction. Gastroenterology 2009; 136: 1552-1560.
96. Schugar RC, Crawford PA. Low-carbohydrate ketogenic diets, glucose homeostasis, and nonalcoholic fatty liver disease. Curr Opin Clin Nutr Metab Care 2012; 15: 374-380.
97. McDevitt RM, Bott SJ, Harding M et al. De novo lipogenesis during controlled overfeeding with sucrose or glucose in lean and obese women. Am J Clin Nutr 2001; 74: 737-746.
98. Faeh D, Minehira K, Schwarz JM et al. Effect of fructose overfeeding and fish oil administration on hepatic de novo lipogenesis and insulin sensitivity in healthy men. Diabetes 2005; 54: 1907-1913.
99. Scribner KB, Pawlak DB, Ludwig DS. Hepatic steatosis and increased adiposity in mice consuming rapidly vs. slowly absorbed carbohydrate. Obesity (Silver Spring) 2007; 15: 2190-2199.
100. Thomas EL, Brynes AE, Hamilton G et al. Effect of nutritional counselling on hepatic, muscle and adipose tissue fat content and distribution in non-alcoholic fatty liver disease. World J Gastroenterol 2006; 12: 5813-5819.
101. Huang MA, Greenson JK, Chao C et al. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J Gastroenterol 2005; 100: 1072-1081.
102. Tamura Y, Tanaka Y, Sato F et al. Effects of diet and exercise on muscle and liver intracellular lipid contents and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2005; 90: 3191-3196.
103. Larson-Meyer DE, Heilbronn LK, Redman LM et al. Effect of calorie restriction with or without exercise on insulin sensitivity, beta-cell function, fat cell size, and ectopic lipid in overweight subjects. Diabetes Care 2006; 29: 1337-1344.
104. Kantartzis K, Thamer C, Peter A et al. High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease. Gut 2009; 58: 1281-1288.
105. Shah K, Stufflebam A, Hilton TN et al. Diet and exercise interventions reduce intrahepatic fat content and improve insulin sensitivity in obese older adults. Obesity (Silver Spring) 2009; 17: 2162-2168.
106. Lazo M, Solga S, Horska A et al. Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. Diabetes Care 2010; 33: 2156-2163.
107. Hatzitolios A, Savopoulos C, Lazaraki G et al. Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia. Indian J Gastroenterol 2004; 23: 131-134.
108. Zelber-Sagi S, Kessler A, Brazowsky E et al. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2006; 4: 639-644.
109. Harrison S, Brunt E, Fecht W, Neuschwander-Tetri BA. Orlistat for overweight subjects with nonalcoholic steatohepatitis (NASH): a randomized prospective trial. Hepatology 2009; 49: 80-86.
110. Berlie HD, Hurren KM. Evaluation of lorcaserin for the treatment of obesity. Expert Opin Drug Metab Toxicol 2013; 9: 1053-1059.
111. Shin JH, Gadde KM. Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity. Diabetes Metab Syndr Obes 2013; 6: 131-139.
112. Chalasani N, Aljadhey H, Kesterson J, Murray MD, Hall SD. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004; 128: 1287-1292.
113. Chalasani N. Statin hepatotoxicity: focus on statin usage in nonalcoholic fatty liver disease. Hepatology 2005; 41: 690-695.
114. Vuppalanchi R, Teal E, Chalasani N. Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes. Am J Med Sci 2005; 329: 62-65.
115. Browning JD. Statins and hepatic steatosis: perspectives from the Dallas Heart Study. Hepatology 2006; 44: 466-471.
116. Lewis JH, Mortensen ME, Zweig S et al. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology 2007; 46: 1453-1463.
117. Athyros VG, Tziomalos K, Gossios TD et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) study: a post-hoc analysis. Lancet 2010; 376: 1916-1922.
118. Athyros VG, Mikhailidis DP, Didangelos TP et al. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin 2006; 22: 873-883.
119. Fernandez-Miranda C, Perez-Carreras M, Colina F et al. A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease. Dig Liver Dis 2008; 40: 200-205.
120. Belfort R, Berria R, Cornell J, Cusi K. Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome. J Clin Endocrinol Metab 2010; 95: 829-836.
121. Fabbrini E, Mohammed BS, Korenblat KM et al. Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2010; 95: 2727-2735.
122. Chan DC, Watts GF, Gan SK, Ooi EM, Barrett PH. Effect of ezetimibe on hepatic fat, inflammatory markers and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet. Diabetes Care 2010; 33: 1134-1139.
123. Yoneda M, Fujita K, Nozaki Y et al. Efficacy of ezetimibe for the treatment of nonalcoholic steatohepatitis: an open-label, pilot study. Hepatol Res 2010; 40: 613-621.
124. Park H, Shima T, Yamaguchi K et al. Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. J Gastroenterol 2011; 46: 101-107.
125. Takeshita Y, Takamura T, Honda M et al. The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial. Diabetologia 2014; 57(5): 878-890.
126. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
127. Belfort R, Harrison SA, Brown K et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006; 355: 2297-2307.
128. Aithal GP, Thomas JA, Kaye PV et al. Randomized, placebocontrolled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008; 135: 1176-1184.
129. Sanyal AJ, Chalasani N, Kowdley KV et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362: 1675-1685.
130. Rakoski M, Singal A, Rogers M, Conjeevaram H. Metaanalysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Therap 2010; 32: 1211-1221.
131. Mendoza C, Ali R, Mathew M et al. Exenatide promotes weight loss and improves insulin secretion, subclinical inflammation, and hepatic steatosis when replaced for pre-meal insulin in T2DM patients (Abstract). Diabetes 2009; 58(Suppl. 1): A507.
132. Cuthbertson DJ, Irwin A, Gardner CJ et al. Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists. PLoS ONE 2012; 7: e50117.
133. Yilmaz Y, Yonal O, Deyneli O et al. Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis. Acta Gastroenterol Belg 2012; 75: 240-244.
134. Lavine JE, Schwimmer JB, Van Natta ML et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 2011; 305: 1659-1668.
135. Hoofnagle JH, Van Natta ML, Kleiner DE et al. Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2013; 38: 134-143.
136. Stephen S, Baranova A, Younossi ZM. Nonalcoholic fatty liver disease and bariatric surgery. Expert Rev Gastroenterol Hepatol 2012; 6: 163-171.
137. Mummadi RR, Kasturi KS, Chennareddygair S, Sood GK. Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2008; 6: 1396-1402.
138. Chavez-Tapia NC, Tellez-Avila FI, Barrientose-Gutierrez T et al. Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Database Syst Rev 2010; (1): CD007340.
139. Charlton M. Evolving aspects of liver transplantation for nonalcoholic steatohepatitis. Curr Opin Organ Transplant 2013; 18: 251-258.
140. Heimbach JK, Watt KD, Poterucha J et al. Combined liver transplantation and gastric sleeve resection for patients with medically complicated obesity and end-stage liver disease. Am J Transplant 2013; 13: 363-368.
141. Smits LP, Bouter KE, de Vos WM, Borody TJ, Nieuwdorp M. Therapeutic potential of fecal microbiota transplantation. Gastroenterology 2013; 145: 946-953.
142. Wieland AC, Quallick M, Truesdale A, Mettler P, Bambha KM. Identifying practice gaps to optimize medical care for patients with nonalcoholic fatty liver disease. Dig Dis Sci 2013; 58: 2809-2816.
143. Poulsen MM, Jørgensen JO, Jessen N, Richelsen B, Pedersen SB. Resveratrol in metabolic health: an overview of the current evidence and perspectives. Ann N Y Acad Sci 2013; 1290: 74-82.
144. Illnait J, Rodríguez I, Mendoza S et al. Effects of D-002, a mixture of high molecular weight beeswax alcohols, on patients with nonalcoholic fatty liver disease. Korean J Intern Med 2013; 28: 439-448.
145. Adorini L, Pruzandski M, Shapiro D. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. Drug Discov Today 2012; 17: 988-997.
146. Mudaliar S, Henry RR, Sanyal AJ et al. Efficacy and safety of the farnesoid x receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 2013; 145: 574-582. e1.
147. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). (2014). The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial(FLINT). [WWW document]. URL http://clinicaltrial.gov/ct2/show/NCT0 1265498 (accessed 2014).
148. Intercept Pharmaceuticals, Inc. (2014). Intercept Announces NASH Primary Endpoint Met: FLINT Trial Stopped Early for Efficacy Based on Highly Statistically Significant Improvement in Liver Histology. [WWW document]. URL http://ir.interceptpharma.com/releasedetail.cfm?ReleaseID=818119 (accessed 2014).